Diabetic Ketoacidosis at Diagnosis Influences Complete Remission After Treatment With

Hematopoietic Stem Cell Transplantation in Adolescents With Type 1 Diabetes

Featured Article:

Weiqiong Gu, M.D., Jiong Hu, M.D., Ph.D., Weiqing Wang, M.D., Lirong Li, M.D., Wei Tang, M.D., Shouyue Sun, M.D., Weijuan Cui, M.D., Lei Ye, M.D.,

Ph.D, Yifei Zhang, M.D., Ph.D., Jie Hong, M.D., Ph.D., Dalong Zhu, M.D., Guang Ning, M.D., Ph.D.

Diabetes Care Volume 35: 1413-1419

July, 2012

Study Objectives

 

Gu W et al. Diabetes Care 2012;35:1413-1419

• To determine whether autologous nonmyeloablative hematopoietic stem cell transplantation (AHSCT) was beneficial for type 1 diabetic adolescents with diabetic ketoacidosis (DKA) at diagnosis

Study Design

• Enrolled 28 patients with type 1 diabetes, aged 14–30 years, in a prospective AHSCT phase II clinical trial

• HSCs harvested from peripheral blood after pretreatment consisting of cyclophosphamide and antithymocyte globulin

• Changes in the exogenous insulin requirement and serum levels of HbA1c, C-peptide, and anti-glutamic acid decarboxylase antibody measured before and after the AHSCT

Gu W et al. Diabetes Care 2012;35:1413-1419

Gu W et al. Diabetes Care 2012;35:1413-1419

Gu W et al. Diabetes Care 2012;35:1413-1419

Gu W et al. Diabetes Care 2012;35:1413-1419

Gu W et al. Diabetes Care 2012;35:1413-1419

Conclusions

• AHSCT appears to be an effective long-term treatment for insulin dependence that achieved a greater efficacy in patients without DKA at diagnosis

Gu W et al. Diabetes Care 2012;35:1413-1419